(Q37800698)

23 August 2017

0 references

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis (English)

1 reference

23 August 2017

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis (English)

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

4 August 2024

0 references

0 references

1 reference

1 reference

Tao Chen

1

1 reference

23 August 2017

Tao Xu

2

1 reference

23 August 2017

Yang Li

3

1 reference

23 August 2017

Chun Liang

4

1 reference

23 August 2017

Juxiang Chen

5

1 reference

23 August 2017

Yicheng Lu

6

1 reference

23 August 2017

Zonggui Wu

7

1 reference

23 August 2017

Shenhong Wu

8

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20952131

4 August 2024

publication date

16 October 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0305737210001593?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

https://api.elsevier.com/content/article/PII:S0305737210001593?httpAccept=text/plain

4 August 2024

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

4 August 2024

published in

Cancer Treatment Reviews

1 reference

23 August 2017

volume

37

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

312-320

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

4 August 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review

4 August 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

4 August 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

4 August 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

4 August 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

4 August 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

4 August 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

4 August 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

4 August 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

4 August 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

4 August 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

4 August 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

4 August 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

4 August 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

4 August 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials

4 August 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

4 August 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

4 August 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Selecting and appraising studies for a systematic review

4 August 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Meta-analysis in clinical trials

4 August 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Quantitative synthesis in systematic reviews

4 August 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

4 August 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

4 August 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

4 August 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

4 August 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer

4 August 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Cardiac side-effects of cancer chemotherapy

4 August 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

A clinicopathologic analysis of adriamycin cardiotoxicity

4 August 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Molecular and cellular mechanisms of anthracycline cardiotoxicity

4 August 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

4 August 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

4 August 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation

4 August 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

4 August 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

Cardiac dysfunction in the trastuzumab clinical trials experience

4 August 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.CTRV.2010.09.001

4 August 2024

Identifiers

1 reference

23 August 2017

1 reference